Announcements Trials
Browse Landscape

Phase

Phase 2 1Phase 1/2 1

Status

Completed 1

Sponsor Class

INDUSTRY 1

Study Type

Interventional 1

Sponsor

Cancer Type

Head & Neck 1

Conditions

Uterine Cervical Neoplasms 1Squamous Cell Carcinoma of Head and Neck 1Recurrence 1Oropharyngeal Neoplasms 1Neoplasms 1Neoplasm Metastasis 1Head and Neck Squamous Cell Cancer 1Head and Neck Neoplasms 1

Interventions

Cisplatin 7pembrolizumab 4Radiotherapy 3Paclitaxel 3fludarabine 2durvalumab 2aldesleukin 2Taxes 2Fluorouracil 2Cyclophosphamide 2Biopsy 2veliparib 1tremelimumab 1prednylidene 1niraparib 1fludarabine phosphate 1exifone 1entinostat 1dostarlimab 1deltacortene 1dehydroftorafur 1bintrafusp alfa protein, human 1advexin 1Tomography, X-Ray Computed 1Specimen Handling 1Radiosurgery 1Radiation 1Prednisone 1Platinum 1Pemetrexed 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Phase 1/2 × Oropharyngeal Neoplasms × MEDI0457 × Clear all
NCT03162224 2022-08-25

Safety and Efficacy of MEDI0457 and Durvalumab in Participants With Human Papilloma Virus (HPV) Associated Recurrent/Metastatic Head and Neck Cancer

MedImmune LLC

Phase 1/2 Completed
35 enrolled 25 charts
Head & Neck

Squamous Cell Carcinoma of Head and Neck, Head and Neck Neoplasms, Neoplasm Metastasis, Neoplasms, Oropharyngeal Neoplasms, Recurrence

Data powered by HemOnc (CC BY 4.0) Colophon âš¡